 |
||
 |
|
|
The UbiScreen technology is protected by two patents issued from the Dominique Thomas’ laboratory (CNRS patents, exclusive licences granted to Cytomics Pharmaceuticals). Cytomics Pharmaceuticals is currently applying for five more patents.
 "Inducible dissociation of SCFMet30 ubiquitin ligase mediates a rapid transcriptional reponse to cadmium" The EMBO Journal 24(3): 521-532
|
|
|
 |
||||||||
     |
||||||||
|
||||||||
     |
||||||||
